IN8bio, Inc.

INAB

US45674E1091

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:30:00 2024-05-21 pm EDT			5-day change	1st Jan Change
1.01 ^USD	-0.98%		-2.88%	-26.81%

May. 13	HC Wainwright Adjusts Price Target on IN8bio to $12.50 From $14, Keeps Buy Rating	MT
May. 13	In8bio Demonstrates Robust and Reproducible Gamma-Delta T Cell Therapy Manufacturing in Oral Presentation At Asgct 2024	CI

Incysus, Ltd has Changed its Name to Incysus Therapeutics, Inc

May 07, 2018 at 12:00 am EDT

On May 07, 2018, Incysus, Ltd changed its name to Incysus Therapeutics, Inc.

Latest news about IN8bio, Inc.

HC Wainwright Adjusts Price Target on IN8bio to $12.50 From $14, Keeps Buy Rating	May. 13	MT
In8bio Demonstrates Robust and Reproducible Gamma-Delta T Cell Therapy Manufacturing in Oral Presentation At Asgct 2024	May. 13	CI
IN8bio, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 09	CI
In8bio, Inc. Doses First Patient in Phase 2 Clinical Trial of Inb-400 in Newly Diagnosed Glioblastoma	Apr. 30	CI
Top Premarket Gainers	Apr. 10	MT
North American Morning Briefing: Traders Await the CPI Report	Apr. 10	DJ
IN8bio, Inc. Announces New Preclinical Data for Gamma-Delta nsCAR-T Cell Therapy Platform at AACR 2024	Apr. 09	CI
Laidlaw Initiates Coverage on IN8bio With Buy Rating, $7.50 Price Target	Mar. 18	MT
IN8bio, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 14	CI
JonesTrading Starts IN8bio With Buy Rating, $5 Price Target	Mar. 13	MT
IN8bio, Inc. to Present New Preclinical Data on Novel Gamma-Delta CAR Platform Candidate at AACR Annual Meeting 2024	Mar. 05	CI
IN8bio Announces Publication on Novel Gamma-Delta T Cell Therapy for Glioblastoma in Frontiers in Immunology	Feb. 14	CI
IN8bio, Inc. announced that it has received $14.442298 million in funding from Bios Equity Partners LP	Dec. 27	CI
Wall Street Set to Open Slightly Higher Tuesday; Annual Inflation Declines to 3.1%	Dec. 12	MT
Top Premarket Gainers	Dec. 12	MT
IN8bio, Inc. Announces Positive Clinical Update Demonstrating Continued Durable Complete Remission in 100% of Evaluable Patients in Phase 1 Trial of INB-100 in Leukemia	Dec. 11	CI
IN8bio Prices $46.9 Million Private Placement; Shares Surge 19%	Dec. 11	MT
IN8bio, Inc. announced that it expects to receive $14.442298 million in funding	Dec. 10	CI
IN8bio, Inc. Appoints Corinne Epperly to the Board of Directors	Dec. 07	CI
IN8bio, Inc.?s INB-200 Demonstrates Extended Progression-Free Survival in Patients with Newly Diagnosed Glioblastoma	Nov. 20	CI
IN8bio, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 09	CI
IN8bio, Inc. Presents Biologic Correlative Data from the Inb-200 Phase 1 Trial in Newly Diagnosed Glioblastoma At the Society for Immunotherapy of Cancer's 38Th Annual Meeting	Nov. 06	CI
IN8bio, Inc. Presents Positive Data Update from Induced Pluripotent Stem Cell Platform at the Society for Immunotherapy of Cancer 38th Annual Meeting	Nov. 03	CI
IN8bio, Inc. to Present New Positive Data from Phase 1 Trial of INB-100 at 2023 American Society of Hematology Annual Meeting	Nov. 02	CI
IN8bio Completes Patient Enrollment for INB-100 Dose Escalation Study, Starts Enrollment for INB-400's Phase 2 Study	23-10-12	MT

IN8bio, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of gamma-delta T cell-based immunotherapies for cancer patients. Gamma-delta T cells are a specialized population of T cells that possess properties, including the ability to differentiate between healthy and diseased tissue. The Company's lead program, INB-400, is in a Phase II clinical trial in which autologous, genetically modified gamma-delta T cells are assessed in glioblastoma (GBM). Its additional programs include Phase I trials in solid and hematologic tumors, including INB-200 for GBM and INB-100 for the treatment of patients with hematologic malignancies that are undergoing hematopoietic stem cell transplantation (HSCT). In addition, the Companyâs DeltEx platform has yielded a portfolio of preclinical programs, including INB-300 and INB-500, focused on addressing acute myeloid leukemia (AML) and other solid and hematological tumor types.

Sector

Biotechnology & Medical Research

Calendar

2024-06-12 - Annual General Meeting

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

1.01 USD

Average target price

7.6 USD

Spread / Average Target

+652.48%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
IN8BIO, INC.	-26.81%	44.46M
VERTEX PHARMACEUTICALS INCORPORATED	+8.63%	114B
REGENERON PHARMACEUTICALS, INC.	+13.17%	107B
BIONTECH SE	-12.76%	22.22B
ARGENX SE	-3.99%	21.28B
BEIGENE, LTD.	-7.19%	17.51B
WUXI APPTEC CO., LTD.	-39.93%	17.17B
NEUROCRINE BIOSCIENCES, INC.	+6.67%	14.14B
SAREPTA THERAPEUTICS, INC.	+33.90%	12.2B
LEGEND BIOTECH CORPORATION	-28.60%	7.83B

Bio Therapeutic Drugs

IN8bio, Inc.

Equities

INAB

US45674E1091

Biotechnology & Medical Research

Incysus, Ltd has Changed its Name to Incysus Therapeutics, Inc

Latest news about IN8bio, Inc.

Chart IN8bio, Inc.

Company Profile

Income Statement Evolution

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Bio Therapeutic Drugs